newsfilter
← Latest News
GlobeNewswire·

Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors